STOCKSCOPE

Axel REE (ASX: AXL) Produces First Rare Earth Carbonate, but Can Its Breakthrough Unlock Commercial Production?

Alison Elzayed

Alison Elzayed

Business & Finance Writer | StockScope

Published:28 Oct 2026
Axel REE (ASX: AXL) Produces First Rare Earth Carbonate, but Can Its Breakthrough Unlock Commercial Production?

Axel REE Limited (ASX: AXL) has achieved a significant metallurgical milestone at its Caladão Project in Brazil, producing its first high-grade mixed rare earth carbonate with the potential to simplify future processing and reduce development costs.

Announced on 27 October 2026, the breakthrough strengthens Axel's proposed in-situ recovery strategy. However, the critical question is whether promising laboratory results can translate into commercially viable production.

Key numbers

  • 54.41% TREO: Total rare earth oxide content in Axel's first mixed rare earth carbonate.
  • 97% recovery: Rare earth precipitation efficiency, increasing to 99% for magnet rare earth oxides.
  • 264.6 million tonnes: Woolrich Mineral Resource, including 110.1 million tonnes classified as Indicated.
  • 708.6 million tonnes: Caladão's combined rare earth Mineral Resource.
  • $5.73 million: Cash reserves at 30 June 2026, against a full-year net loss of $3.64 million.

A processing breakthrough could change Woolrich's economics

The latest results represent more than another exploration milestone.

Independent laboratory testing successfully converted rare earth-bearing solutions into a mixed rare earth carbonate containing 54.41% total rare earth oxides.

Importantly, the product contained 35.9% magnet rare earth oxides within its rare earth basket, including commercially valuable neodymium, praseodymium, dysprosium and terbium.

These elements are essential ingredients in permanent magnets used across electric vehicles, wind turbines and advanced industrial equipment.

The strongest commercial implication, however, lies in processing efficiency.

Axel achieved its precipitation results without a dedicated impurity-removal stage in the laboratory circuit.

Removing this step from a commercial processing flowsheet could potentially reduce equipment requirements, reagent consumption and operating complexity.

That advantage remains unproven at scale, but it provides a credible technical basis for further development.

The laboratory test produced just 15.11 grams of dried carbonate, demonstrating process feasibility rather than commercial production capability.

A larger resource strengthens the development opportunity

Axel's processing milestone follows a substantial expansion of its Brazilian mineral resources.

In September 2026, the company upgraded Woolrich's Mineral Resource to 264.6 million tonnes grading 1,101 parts per million TREO, more than doubling its previous estimate.

The upgrade included 110.1 million tonnes of Indicated Resources, representing approximately 42% of Woolrich's total.

Across Caladão, rare earth resources increased 24% to 708.6 million tonnes, while gallium resources expanded 31% to 575.7 million tonnes.

These developments strengthen geological confidence and provide a larger potential resource base for future development studies.

Nevertheless, Mineral Resources are not Ore Reserves, and their size does not establish profitability.

Recoverable volumes, processing costs, environmental approvals and development expenditure will ultimately determine the project's economic potential.

Cash reserves and development costs remain critical

Axel remains an exploration and development-stage company without established operating revenue.

Its financial year ended 30 June 2026 produced a net loss of $3.64 million, alongside closing cash reserves of $5.73 million.

While the cash balance provides funding flexibility, it should not be interpreted as sufficient capital for commercial development.

Upcoming field trials, engineering studies and environmental assessments will require further expenditure.

Additional financing could become necessary as development progresses, potentially introducing shareholder dilution.

Traditional earnings multiples are therefore unsuitable for assessing Axel's valuation.

We believe a more meaningful assessment will eventually depend on risk-adjusted project economics, including recoverable rare earth volumes, operating costs, initial capital expenditure and sustainable production capacity.

Without these inputs, any definitive conclusion that Axel is undervalued would be premature.

Can laboratory success survive real-world conditions?

Axel's next major challenge is demonstrating that its recovery process works consistently outside the laboratory.

The company is preparing controlled in-situ recovery field testing at Woolrich, supported by hydrogeological, geotechnical and environmental assessments.

Successful testing would provide important evidence about solution recovery, reagent consumption, impurity behaviour and overall extraction efficiency.

Meanwhile, Axel is accelerating exploration at its separate Caldas Project following renewed corporate interest in Brazil's Poços de Caldas rare earth district.

Although Caldas provides additional exploration potential, Woolrich remains the more immediate development priority.

Insight: Axel's real opportunity lies in simplifying rare earth production

What stands out to us is the potential relationship between Axel's expanding resource base and its emerging processing advantages. Achieving 97% rare earth precipitation without a dedicated impurity-removal stage suggests a potentially less complex development pathway, but precipitation efficiency is not equivalent to overall mineral recovery. The company's opportunity becomes substantially more credible if controlled field testing confirms consistent recoveries, manageable reagent consumption and competitive operating costs. The next decisive measure will be independently demonstrated field-scale recovery efficiency.

The verdict: A promising breakthrough facing its biggest test

Axel has strengthened its technical foundations through resource growth and successful carbonate production.

The opportunity is compelling enough to warrant attention, particularly given demand for magnet rare earths and the potential benefits of simplified processing.

However, commercial viability remains unproven.

The next Woolrich field validation results will be critical in determining whether Axel can progress from laboratory success towards a financially sustainable rare earth development.

Alison Elzayed

Alison Elzayed

(Business & Finance Writer | StockScope)

Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...